Reading information: diagnostic use
Molecules carried by vesicles can offer information about their cells of origin. Diagnostic use measures a molecular signal in a sample rather than administering exosomes. This distinction shows why “exosome treatment” does not describe the whole field.
In the independent validation cohort of 519 men in a 2016 multicenter study, a urinary exosome gene-expression assay helped discriminate risk of high-grade prostate cancer. It was studied to support biopsy decisions, not as a stand-alone diagnosis or screening test for every cancer.
Delivering cargo: precision-medicine research
Another opportunity is engineering vesicles to carry selected molecular cargo. A 2025 phase I pancreatic cancer study evaluated engineered exosomes carrying KRAS G12D-targeted siRNA. This is a purpose-built platform distinct from a cosmetic preparation.
The single-arm study prioritized safety, tolerability and target engagement. Some patients had stable disease; a comparative survival benefit was not established. The study is not a recommendation for routine cancer treatment.
How to assess the opportunity
For diagnostics, the question is whether a test supports the right decision for the right patient. For drug delivery, reaching the target must ultimately translate into improved clinical outcomes. Both areas are compelling, but their success criteria and development stages differ.